Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Validation of a Rapid Automated Lymphoma Next-Generation Sequencing Panel

  • Michael Krigstein (Department of Molecular Pathology, St Vincent's Hospital) ;
  • Emily Jude (Department of Molecular Pathology, St Vincent's Hospital) ;
  • Aleisha Jaffrey (Department of Molecular Pathology, St Vincent's Hospital) ;
  • Stephen Bye (Department of Molecular Pathology, St Vincent's Hospital) ;
  • Bin Wang (Department of Molecular Pathology, St Vincent's Hospital) ;
  • Min Ru Qiu (Department of Molecular Pathology, St Vincent's Hospital) ;
  • David Ma (Department of Molecular Pathology, St Vincent's Hospital)
  • Received : 2025.05.14
  • Accepted : 2025.09.18
  • Published : 2026.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Our genomic understanding of lymphomas, a heterogeneous group of neoplasms, has grown exponentially. The latest World Health Organization (WHO) and International Consensus classifications reflect the importance of genetic assessment in the diagnosis and prognostication of and therapeutic decision making in lymphoid neoplasms. To address this clinical need for routinely available and timely testing, we aimed to validate the Ion AmpliSeq Liverpool Lymphoid Network Panel (IALLNP; Thermo Fisher Scientific, Waltham, MA, USA). Methods: We clinically validated the IALLNP on the Ion Torrent Genexus Sequencer (Thermo Fisher Scientific). The panel detects single-nucleotide variants (SNVs) and insertions/deletions (indels) in 60 clinically relevant genes. The validation set included a commercial control and 54 DNA samples covering the spectrum of clinically aggressive and indolent lymphomas. Results: After optimizing for poor coverage regions, recurrent artifacts, and false-negative calls, the panel showed good performance in terms of depth of coverage, on-target reads, and uniformity. Its sensitivity for SNVs and indels at a lower limit of detection of 5% variant allele frequency (VAF) was 100%. Specificity in variant-negative samples was 100%, and the mean per-sample number of false-positive variants-which were easily identifiable and excluded upon interrogation of raw data-was 0.4. The panel demonstrated 92.8% reproducibility; however, all nonreproducible variants fell below the 5% VAF analytical threshold. Conclusions: The IALLNP is an accurate and reproducible next-generation sequencing panel that delivers genetic results for lymphoid neoplasms in a clinically meaningful time-frame.

Keywords

Acknowledgement

The authors acknowledge the generous support provided by clinical bioinformatics consultant Ms Lauren Olafson.

References

  1. de Leval L, Alizadeh AA, Bergsagel PL, Campo E, Davies A, Dogan A, et al. Genomic profiling for clinical decision making in lymphoid neoplasms. Blood 2022;140:2193-227. https://doi.org/10.1182/blood.2022015854
  2. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022;36:1720-48. https://doi.org/10.1038/s41375-022-01620-2
  3. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022;140:1229-53. https://doi.org/10.1182/blood.2022015851
  4. Falini B, Martino G, Lazzi S. A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas. Leukemia 2023;37:18-34. https://doi.org/10.1038/s41375-022-01764-1
  5. Fend F, van den Brand M, Groenen PJ, Quintanilla-Martinez L, Bagg A. Diagnostic and prognostic molecular pathology of lymphoid malignancies. Virchows Arch 2024;484:195-214. https://doi.org/10.1007/s00428-023-03644-0
  6. Stuckey R, Luzardo Henríquez H, de la Nuez Melian H, Rivero Vera JC, Bilbao-Sieyro C, Gómez-Casares MT. Integration of molecular testing for the personalized management of patients with diffuse large B-cell lymphoma and follicular lymphoma. World J Clin Oncol 2023;14:160-70. https://doi.org/10.5306/wjco.v14.i4.160
  7. Breinholt MF, Schejbel L, Gang AO, Nielsen TH, Pedersen LM, Høgdall E, et al. Next generation sequencing in routine diagnostics of mature non-Hodgkin's B-cell lymphomas. Eur J Haematol 2023;111:583-91. https://doi.org/10.1111/ejh.v111.4
  8. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305-15. https://doi.org/10.1056/NEJMoa1014209
  9. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 2012;367:826-33. https://doi.org/10.1056/NEJMoa1200710
  10. Rosenquist R, Rosenwald A, Du MQ, Gaidano G, Groenen P, Wotherspoon A, et al. Clinical impact of recurrently mutated genes on lymphoma diagnostics: State-of-the-art and beyond. Haematologica 2016;101:1002-9. https://doi.org/10.3324/haematol.2015.134510
  11. Vallois D, Dobay MP, Morin RD, Lemonnier F, Missiaglia E, Juilland M, et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood 2016;128:1490-502. https://doi.org/10.1182/blood-2016-02-698977
  12. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018;24:679-90. Erratum in: Nat Med 2018;24:1290-1.
  13. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 2018;378:1396-407. https://doi.org/10.1056/NEJMoa1801445
  14. Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: A Haematological Malignancy Research Network report. Blood 2020;135:1759-71. https://doi.org/10.1182/blood.2019003535
  15. Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 2020;37:551-68.e14. https://doi.org/10.1016/j.ccell.2020.03.015
  16. Paul P, Stüssi G, Bruscaggin A, Rossi D. Genetics and epigenetics of CLL. Leuk Lymphoma 2023;64:551-63. https://doi.org/10.1080/10428194.2022.2153359
  17. László T, Kotmayer L, Fésüs V, Hegyi L, Gróf S, Nagy Á, et al. Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation. J Pathol Clin Res 2024;10:e351.
  18. Julia E and Salles G. EZH2 inhibition by tazemetostat: Mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma. Future Oncol 2021;17:2127-40. https://doi.org/10.2217/fon-2020-1244
  19. Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, et al. Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors. N Engl J Med 2022;386:735-43. https://doi.org/10.1056/NEJMoa2114110
  20. Tam CS, Balendran S, Blombery P. Novel mechanisms of resistance in CLL: Variant BTK mutations in second-generation and noncovalent BTK inhibitors. Blood 2025;145:1005-9. https://doi.org/10.1182/blood.2024026672
  21. Blombery P. Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease. Leuk Lymphoma 2020;61:257-62. https://doi.org/10.1080/10428194.2019.1660974
  22. Blombery P, Thompson ER, Nguyen T, Birkinshaw RW, Gong JN, Chen X, et al. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood 2020;135:773-7. https://doi.org/10.1182/blood.2019004205
  23. UniProt Consortium. UniProt: The universal protein knowledgebase in 2025. Nucleic Acids Res 2025;53:D609-17. https://doi.org/10.1093/nar/gkae1010
  24. Sondka Z, Dhir NB, Carvalho-Silva D, Jupe S, Madhumita, McLaren K, et al. COSMIC: A curated database of somatic variants and clinical data for cancer. Nucleic Acids Res 2024;52:D1210-7. https://doi.org/10.1093/nar/gkad986
  25. Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature 2024;625:92-100.
  26. de Andrade KC, Lee EE, Tookmanian EM, Kesserwan CA, Manfredi JJ, Hatton JN, et al. The TP53 Database: Transition from the International Agency for Research on Cancer to the US National Cancer Institute. Cell Death Differ 2022;29:1071-3. https://doi.org/10.1038/s41418-022-00976-3
  27. Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn 2017;19:4-23. https://doi.org/10.1016/j.jmoldx.2016.10.002
  28. Sujobert P, Le Bris Y, de Leval L, Gros A, Merlio JP, Pastoret C, et al. The need for a consensus next-generation sequencing panel for mature lymphoid malignancies. HemaSphere 2019;3:e169. https://doi.org/10.1097/HS9.0000000000000169